A 5-Year Open Label Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in the Treatment of Postmenopausal Women With Osteoporosis

Trial Profile

A 5-Year Open Label Extension to: A Randomized, Double-Blind, Placebo-Controlled Study to Assess the Safety, Tolerability, and Efficacy of Odanacatib (MK-0822) in the Treatment of Postmenopausal Women With Osteoporosis

Completed
Phase of Trial: Phase II

Latest Information Update: 11 Apr 2016

At a glance

  • Drugs Odanacatib (Primary)
  • Indications Bone resorption; Postmenopausal osteoporosis
  • Focus Therapeutic Use
  • Acronyms Cat-K 11b
  • Sponsors Merck Sharp & Dohme
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 05 Apr 2014 Results of an analysis from the 5-year extension phase presented at the 2014 World Congress on Osteoporosis, Osteoarthritis and Musculoskeletal Diseases.
    • 03 Nov 2012 Planned number of patients changed from 246 to 375 as reported by European Clinical Trials Database.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top